关于CYP2D6代谢器状态对Ondansetron在怀孕早期诱导恶心和吐的疗效的影响:一个案例对照研究
Michelle Liu1, Megan M Shuey2,3, Sabrina E Holley4
1Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Clinical and translational science
|March 13, 2026
概括
这项研究发现,根据CYP2D6代谢器状态,在怀孕期间对恶心和吐的安丹塞特朗疗效没有显著差异. 需要进一步的研究来证实这些发现在孕妇患者.
科学领域:
- 药物基因组学 药物基因组学
- 生殖医学是一种生殖医学.
- 临床药理学 临床药理学
背景情况:
- 丹塞特朗通常用于怀孕中恶心和吐 (NVP).
- CYP2D6酶活性会影响药物代谢,超快代谢剂可能会经历丹塞功效的降低.
- 在NVP中对CYP2D6对丹塞特朗反应的影响的现实数据有限.
研究的目的:
- 调查CYP2D6遗传变异与ONDANSETRON在NVP.怀孕患者的疗效之间的关联.
- 为了确定CYP2D6代谢器状态 (差,中等,正常,超快) 是否会影响ondenansetron反应.
主要方法:
- 对264名接受丹塞治疗NVP的孕妇进行了回顾性队列研究.
- 对11种CYP2D6变体和拷贝数变异进行基因型定型,以确定活性评分 (AS) 和代谢器状态.
- 多变量回归分析调整为相关的共变量.
主要成果:
- 在CYP2D6代谢器状态和丹塞反应之间没有发现显著的关联.
- 与低/中等代谢剂 (OR 1.53) 相比,超速代谢剂/正常代谢剂的非响应风险不显著增加.
- 较高的CYP2D6活性评分也趋向于增加不响应风险 (OR 1.22).
结论:
- 在这组孕妇中,CYP2D6代谢器状态和活性评分没有显著影响丹塞的疗效.
- 需要进行进一步的前性研究,以确定CYP2D6在怀孕期间对丹塞反应的作用.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
763
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
763
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
90
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
90
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K
Pharmacogenetics of Drug Metabolism: Overview
87
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
87
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
835
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
835
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83

